ELF3 Is a Target That Promotes Therapeutic Efficiency in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Epidermal growth factor receptor (EGFR) mutations drive non-small cell lung cancer (NSCLC).
• Resistance to EGFR tyrosine kinase inhibitors (TKIs) emerges due to secondary mutations in over half of treated patients.
• Identifying alternative therapeutic targets is crucial for overcoming TKI resistance in NSCLC.

Purpose of the Study:

• To identify and validate alternative therapeutic targets for NSCLC in patients resistant to EGFR TKI therapy.
• To investigate the role of ELF3 as a potential target in NSCLC treatment.
• To evaluate the efficacy of auranofin in overcoming EGFR TKI resistance.

Main Methods:

• Transcriptome profiling was employed to identify putative therapeutic targets in NSCLC.
• Putative targets were validated through in vitro and in vivo experiments.
• The effects of ELF3 knockdown and auranofin (PKCι inhibitor) on cancer cell death were assessed.

Main Results:

• ELF3 was identified as differentially expressed in NSCLC.
• Knockdown of ELF3 significantly increased cell death in lung cancer cells with K-Ras mutations and EGFR L858R/T790M mutations.
• Auranofin, an inhibitor of protein kinase C iota (PKCι) upstream of ELF3, effectively induced cell death.

Conclusions:

• Blocking ELF3 is a viable strategy to induce cell death in NSCLC harboring K-Ras and EGFR T790M/L858R mutations.
• Auranofin demonstrates potential as an effective alternative drug to overcome EGFR TKI resistance in NSCLC.
• Targeting ELF3 presents a promising therapeutic avenue for resistant NSCLC.